Phase I Clinical Study on the Long-term Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Solid tumor.

Phase I Clinical Study on the Long-term Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Solid tumor. - Phase I Clinical Study on the Long-term Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Solid Tumor.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008006

Enrollment

Registered

2012-05-21

Start date

2012-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Solid Tumor

Interventions

CHP-NY-ESO-1, MIS416

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Completion of the study 'Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Urothelial or Prostate Cancer' or 'Phase I Study on the Combination Therapy of IMF-001 and MIS416 for the Treatment of Patients with NY-ESO-1-expressing malignant solid tumor'. 2) Non-progressive disease on the study termination image test of 'Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1-expressing Refractory Urothelial or Prostate Cancer' or 'Phase I Study on the Combination Therapy of IMF-001 and MIS416 for the Treatment of Patients with NY-ESO-1-expressing malignant solid tumor'. 3) Cooperativeness to written informed consent must be obtained and documented.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Adverse effects.	—

Secondary

Measure	Time frame
Immune response, QOL, and the change in serum PSA (prostate cancer only).	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026